The Panther Group – Venture Capital for Growth Stage Cannabis Companies
Join Our Exclusive Family Office Investor Event to learn more about The Panther Group.
Family Office Attendees Will Benefit from High-Level Insights.
The Panther Group:
-Venture capital consulting group preparing growth-stage cannabis companies for long-term, profitable success.
-Advising companies with notable traction in the cannabis industry
-Access to capital, leads, and digital advertising solutions.
The Panther EcoSystem:
-Extensive web of over 6K cannabis professionals.
-Network that spans to more than 20 sectors of the cannabis industry.
-Vetted database and directory of cannabis companies and seasoned investors.
Family Wealth Leadership – Generational Wealth Dangers!
Join Family Office Networks and Family Wealth Leadership to learn how your family can avoid the historical fact of 70% of wealth being lost when it transitions to the next generation and gone in three generations.
Trevian Capital: Bridge Lending Strategy – Monthly Current Income, Downside Principal Protection, and Diversification
Join Our Exclusive Family Office Networks Investor Event to learn more about Trevian Capital.
Trevian Capital is an established company that has been originating and servicing first-mortgage bridge loans on multifamily and commercial real estate throughout the US since 2013, accounting for approximately $550,000,000 in loans across 67 transactions in 18 states. Trevian’s strategy provides investors with current monthly income from first-mortgage bridge loans targeting net return to investors of approximately 10% annually.
Trevian believes bridge lending opportunities are prevalent in bull and bear markets alike, but market dislocations including the current one create outsized opportunity for deal volume and outsized risk-adjusted yield.
Jarabek & Company – Power of Politics
Join the Family Office Networks webinar series featuring Jarabek & Company.
Jarabek & Company is a full-service advisory firm that is passionate about providing government affairs strategy and integrated business consulting. They are committed to achieving government relations objectives and their clients’ business goals, from strategy to implementation, both at home and abroad.
EPS – Get Off The Grid & Be The Change
Join Our Exclusive Family Office Networks Investor Event to learn more about:
-Benefits of Renewable Energy
-Importance of Powering Small and Remote Global Communities
-Investment Opportunities in Energy’s Distributed Generation Sector
-EPS Biomass Turbine’s Game-Changing Technology
Join FON and Michael Daly, President and CEO of Enviro Power Solutions, to learn how to profit from an investment of up to US$18 million for up to a 45% common share ownership in this early-stage distributed energy company.
GREIF – Growing Free Cash Flow Through the Cycle
Join Our Exclusive Family Office Networks Investor Event on March 23rd at 1:00 pm ET to learn more about Greif, Inc.
Greif, Inc. (NYSE: GEF, GEF.B) is a global leader in industrial packaging products and services and is pursuing its vision to become the world’s best performing customer service company in industrial packaging. The company pays an industry leading dividend and offers exposure to an improving global macro-economic backdrop through its extensive and leading product offerings in a variety of different packaging substrates. Greif’s stable ownership base includes a sizable family component focused on long term value creation and steady return of capital to shareholders.
Join us to learn more about this packaging leader and the opportunities it sees ahead as the world rebounds from the COVID-19 pandemic.
Proteus the Future of Commercial Ocean Exploration
Join the Family Office Networks Webinar Series featuring Proteus, the International Space Station of the Ocean. Proteus is a global collaborative platform for researchers, academics, government, and corporations to accelerate marine science. The research conducted on Proteus will significantly contribute to furthering R&D, technological innovations, and enable advancement in renewable energy solutions, future medicines and cures, and sustainable food sources.
Soligenix – Filling Urgent Healthcare Needs by Targeting Unaddressed Rare Diseases
Join the Family Office Networks’ Webinar Series featuring Soligenix, Inc.
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.
A Public Health Solutions business segment, funded entirely by the US Government to the amount of approximately $70 million to date, developing vaccines and therapeutics for military and civilian applications in the areas of ricin exposure, emerging and antibiotic resistant infectious disease, and viral disease including Ebola, Marburg and COVID-19.
Nasdaq: SNGX Stock Snapshot as of 01/22/21 Market Cap: ~ $61 Million Stock Price: $1.72 Avg Daily Vol (50D): ~ 2.3 Million
Shares Outstanding: ~ 35.5 Million
Family Office Networks Series A Capital Raise
Fintech companies backed by venture capital firms and family offices raised almost $38.5 billion last year and are set to exceed that in 2021. Family Office Networks is well-positioned as one of the only fintech companies serving the family office sector, making growth trajectory strong. Join Founder & CEO of FON, Andrew Schneider, for this webinar discussing the FON Series A capital raise launch.
PSY Therapeutics – New Approach to Tackling Alzheimer’s Disease
Join the Family Office Networks’ Webinar Series featuring Psy Therapeutics, Inc.
PSY Therapeutics, Inc. is an emerging biopharmaceutical company focused on developing transformative medicines to treat serious neurodegenerative and neuropsychiatric disorders. The Company’s novel approach to customized small molecule drug discovery and development combines cutting-edge technology with an extensive network of collaborators to drive R&D innovation and productivity.
In this webinar, the PSY team will focus on their unique tau program for disease-modifying treatment of Alzheimer’s Disease (AD) and related tauopathies. They will take a deeper look at the growing patient population, assess lessons learned from other AD program failures and detail Psy’s opportunity for a new approach to disease treatment.